Alcon

Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal edema, and one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness.

LENSAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, established in 2004. It specializes in the design, development, and marketing of advanced femtosecond laser systems aimed at improving cataract surgery outcomes. The company's flagship product, the LENSAR Laser with Streamline IV, enhances the precision and efficiency of refractive cataract surgery by incorporating advanced features such as superior imaging capabilities and customizable treatment planning. This system assists surgeons in managing astigmatism and optimizing refractive results through innovative technology like the proprietary Augmented Reality™ 3-D model and the IntelliAxis Refractive Capsulorhexis® feature. These advancements facilitate accurate toric intraocular lens alignment and streamline surgical workflows, ultimately improving patient outcomes. LENSAR continues to expand its platform's capabilities, enabling the treatment of additional corneal conditions and enhancing the overall surgical experience for both patients and surgeons.

Ocumension Therapeutics is a China-based ophthalmic pharmaceutical company focused on the identification, development, and commercialization of innovative therapies for eye diseases. The company aims to address significant unmet medical needs in the ophthalmic field by providing comprehensive pharmaceutical solutions. Its extensive portfolio includes various product candidates such as OT-401, OT-101, OT-301, OT-1001, OT-502, OT-202, OT-503, and several others. Ocumension Therapeutics has established a platform that integrates specialized capabilities across the entire development cycle of ophthalmic drugs, encompassing research, manufacturing, and commercialization. This strategic approach positions the company to potentially lead the ophthalmology market in China, leveraging its first-mover advantage to enhance patient care.

BELKIN Vision focuses on developing a laser device that aids healthcare professionals in the treatment of glaucoma. The company's technology offers a non-invasive, non-contact, instantaneous, painless, and automated approach to laser therapy. By promoting accessibility to first-line drop-less glaucoma care, BELKIN Vision enables any ophthalmologist to effectively treat patients. This innovation aims to enhance treatment outcomes and improve the overall quality of care for individuals suffering from glaucoma.

Aerie Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases, including glaucoma, dry eye, and retinal conditions. The company's key products include Rhopressa, a once-daily eye drop designed to lower elevated intraocular pressure in patients with glaucoma or ocular hypertension, and Rocklatan, a fixed-dose combination of Rhopressa and latanoprost, also aimed at reducing intraocular pressure in open-angle glaucoma patients. Additionally, Aerie is developing AVX-012, a clinical-stage candidate for dry eye, alongside AR-1105 and AR-13503, which are sustained-release implants targeting retinal diseases. Founded in 2005, Aerie Pharmaceuticals is headquartered in Durham, North Carolina, and has a collaborative research agreement with DSM, reflecting its commitment to advancing eye care solutions.

EYSUVIS Portfolio of dry eye disease therapies and medications designed to make ocular surgery easier.

Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal edema, and one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company specializes in a minimally invasive intracanalicular scaffold that alleviates high intraocular pressure by restoring the natural outflow pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its primary focus on glaucoma, Ivantis intends to explore innovative treatments for other ophthalmic diseases as it expands its product offerings. The company also provides a Session Persistence Server to support clinical trials, ensuring data protection for telnet task workers and terminal emulation users across various devices and operating systems.

TrueVision Systems specializes in high-definition digital imaging and 3D visualization technology aimed at enhancing stereomicroscopy in surgical and educational environments. The company has developed a patented vision system and smart medical software packages applicable across various surgical disciplines. Founded by Dr. Michael Weissman, a leading expert in digital stereoscopic imaging, TrueVision addresses the need for improved visualization in existing surgical microscopes. The firm's flagship product, the TrueVision 3DHD vision system, is designed for microsurgery and incorporates advanced features such as robotics, integrated patient data, and intraoperative connectivity to boost surgical accuracy and efficiency. In addition to manufacturing its own products, TrueVision licenses its technology to both medical and non-medical manufacturers for diverse stereoscopic visualization applications. With a team comprised of industry veterans and PhD-level technical staff, the company is committed to developing innovative solutions that enhance surgical outcomes and improve the education of microsurgery.

Tear Film Innovations Inc. is a medical device company based in San Diego, California, specializing in the treatment of evaporative dry eye and related conditions such as meibomian gland dysfunction (MGD) and blepharitis. Founded in 2014, the company has developed the iLux Dry Eye Treatment System, a handheld device that allows eye care professionals to quickly evaluate and treat dry eye patients in under ten minutes. The iLux system uses targeted heating and compression to unblock meibomian glands, addressing the most common form of dry eye that affects over 330 million people worldwide. Additionally, the company offers BlephaRx, which targets both the symptoms and underlying causes of evaporative dry eye. As of December 2018, Tear Film Innovations operates as a subsidiary of Alcon, Inc.

Transcend Medical is focused on the development of medical devices for the treatment of glaucoma, a cause of adult irreversible blindness. It is estimated that nearly four million people in the US and over 60 million worldwide are afflicted with the disease today and the numbers are expected to grow to nearly six million in the US, and to over 70 million worldwide by the year 2015. In 2005, Transcend Medical was the first company to spin out of ForSight Labs, an incubator solely focused on ophthalmic innovations. Transcend Medical was granted CE mark for the CyPass Micro-Stent® in 2008, and is being evaluated in several clinical studies in the US and abroad, including the COMPASS multi-center clinical trial.

WaveTec Vision is a small company with a big idea — and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

SensoMotoric Instruments (SMI) is a world leader in dedicated computer vision applications. Working closely with their clients, they have more than 20 years experience in developing and marketing application-specific gaze & eye tracking systems and OEM solutions. More than 6,000 of their eye tracker systems in operation worldwide are testimony to their continuing success in providing innovative products and outstanding services.

LensX Lasers is a developer of surgical lasers used for the reparation of cataracts.

Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.

Wavelight designs, manufactures and markets innovative laser systems for a range of medical, aesthetic and industrial applications. Medical applications include ophthalmology, dermatology and urology.